News

May 25, 2022

Neuropathix, Inc. Highlights Revenue Related to its Grant Award with NIH-NINDS

April 13, 2022

Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019

April 6, 2022

Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding

January 25, 2022

Neuropathix, Inc. Welcomes Daniele Piomelli, PhD, MD to the Company’s Scientific Advisory Board

January 18, 2022

Neuropathix, Inc. Receives Patent Grant from India for Its Novel Anti-Inflammatory Compounds

November 17, 2021

Neuropathix, Inc. Chooses Purisys for Process Optimization and Scale Up of Its Lead Drug Candidate KLS-13019

September 28, 2021

Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)

August 24, 2021

Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company’s Over-The-Counter Cosmeceutical Assets

August 12, 2021

Neuropathix, Inc. Appoints Michael Ropacki, PhD to the Company’s Scientific Advisory Board

July 20, 2021

Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders

July 6, 2021

Temple research finds that tweaking CBD may help it curb pain and opioid use in mice

May 20, 2021

Philly Pharmacologists Are Developing a Promising Pain-Relieving CBD Analog Drug

November 6, 2020

Kannalife, Inc. Rebrands as Neuropathix, Inc. and Unveils New Ticker Symbol

September 17, 2020

Kannalife, Inc. Appoints Dr. Tage Honoré as Chairman of the Company’s Board of Advisors

June 30, 2020

Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories

April 14, 2020

Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine™ Versus CBD

April 1, 2020

Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™

February 18, 2020

Kannalife Bolsters its Global Intellectual Property Portfolio with New Chinese-Issued Patent

February 11, 2020

Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN

January 28, 2020

Kannalife, Inc. CEO Recaps 2019 Advances and Potential Ahead

Get the Latest in Neuropathix News

Subscribe